Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment. Tsai TF. Br J Dermatol 2020 Feb 3. doi: 10.1111/bjd.18869.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Tsai TF. Secukinumab in patients with psoriasis who have responded inadequately to tumour necrosis factor inhibitor treatment. Br J Dermatol 2020 Feb 3. doi: 10.1111/bjd.18869.
PMID: 32017027